Nab-Paclitaxel
Based on 8 publication(s) in Google Scholar
Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Assay : 99.9%
- Masse moléculaire:853.91 Da
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-17026
GemcitabineDNA Synthesis Inhibitor -
HY-17371
OxaliplatinDNA Synthesis Inhibitor -
HY-90006
5-FluorouracilThymidylate Synthase Inhibitor -
HY-B0015
PaclitaxelAntitumor Agent -
HY-B0011
DocetaxelMicrotubule Depolymerization Inhibitor -
HY-16562
IrinotecanTopoisomerase I Inhibitor -
HY-17394
CisplatinDNA Alkylator -
HY-10820
Pemetrexed -
HY-17393
CarboplatinDNA Synthesis Inhibitor -
HY-B0003
Gemcitabine hydrochlorideDNA Synthesis Inhibitor -
HY-13704
SN-38Topoisomerase I Inhibitor -
HY-17364
TemozolomideDNA Alkylator
Publications Citing Use of MedChemExpress (MCE) Nab-Paclitaxel
More- Mol Cancer. 2024 Sep 30;23(1):215. [Abstract]
- Biomater Adv. 2026 Feb 18:183:214782. [Abstract]
- Precis Clin Med. 2026 Mar 14;9(2):pbag009. [Abstract]
- Int Immunopharmacol. 2026 Jun 15:179:116595. [Abstract]
- ACS Appl Polym Mater. 2026 Mar 11;8(6):4031-4044.
- Mol Oncol. 2026 Jun 5. [Abstract]
- Cancer Res Commun. 2026 Jul 1;6(7):1794-1813.
- Int J Refrig. 2026 Jun 4;189:107003.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Activité biologique
Description
In Vitro
Nab-Paclitaxel (0.1 nM-10 μM, 72 h) is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line[3].
Nab-Paclitaxel (12-120 nM, 48 h) increases apoptotic RH4 cells and most cells detaches from the coveslips with higher concentration (60 or 120 nM)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Three rhabdomyosarcoma cell lines(RH4, RH30, and RD), seven neuroblastoma cell lines (CHLA-20, CHLA-15, CHLA-90, LAN-5, SK-N-BE(2), BE(2)C, and SH-SY5Y) and one osteosarcoma cell line (KHOS)
-
Concentration:0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, 10 μM
-
Incubation Time:72 h
-
Result:Reduced the cell viability of the three rhabdomyosarcoma cell lines with IC50 ranging from 0.56 to 4.68 nM.
Exhibited dose-dependent cytotoxicity in seven neuroblastoma cell lines, where CHLA-20 has the highest IC50 of 36 nM.
In Vivo
Nab-Paclitaxel (2-10 mg/kg, i.v., daily) significantly inhibits tumor growth with 5 and 10 mg/kg in neuroblastoma (SK-N-BE (2) and CHLA-20) xenograft (s.c.) mice[3].
Nab-Paclitaxel (50 mg/kg, i.v., weekly) has the strongest antitumor activity and significantly prolongs animal survival[3].
Nab-Paclitaxel (10 mg/kg, i.v., 5 consecutive days or 50 mg/kg, i.v., weekly) displays lower plasma paclitaxel concentrations but higher intratumor paclitaxel concentrations in both rhabdomyosarcoma and neuroblastoma mice model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NOD/SCID (nonobese diabetic/severe combined immunodeficient) mice 4- to 6-week old bearing rhabdomyosarcoma (RH4 and RD) xenografts[3]
-
Dosage:30, 50 mg/kg
-
Administration:Intravenous injection (i.v.), administer on day 1, 8, 15 then 52, 59, 66
-
Result:Exhibited lower toxicity to mice compared with Paclitaxel.
Increased local relapse-free intervals.
Significantly inhibited tumor growth and led to tumor shrinkage.
Remained sensitivity in mice with relapse RH4 xenografts against Nab-Paclitaxel whilst the xenografts were drug resistant against Paclitaxel.
Led to complete regression after day 29, but a few had relapsed tumor after 37 to 42 days.
-
Animal Model:Female NOD/SCID (nonobese diabetic/severe combined immunodeficient) mice 4- to 6-week old bearing rhabdomyosarcoma or neuroblastoma xenografts[3]
-
Dosage:10 mg/kg for 5 consecutive days or 50 mg/kg weekly
-
Administration:Intravenous injection (i.v.)
-
Result:Significantly increased apoptotic cell population in a dose-dependent manner.
Increased phospho-histone H3-positive cells in a dose-dependent manner.
Induced G2-M cell-cycle arrest.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Solid
-
Masse moléculaire 853.91 Da
-
Color White to off-white
-
SMILES
[Nab-Paclitaxel]
-
Synonyms
Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer. [Abstract]2024 Sep 30;23(1):215. PMID: 39350121
Nab-Paclitaxel purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Sep 30;23(1):215. [Abstract]
Sulindac K-80003 restored sensitivity to AG (10 nM, 48 h) significantly shrunk tumors arising and prolonged the median survival in the corresponding PDOX model.
Nab-Paclitaxel purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Sep 30;23(1):215. [Abstract]
Mice were treated with saline, the dual combination of gemcitabine (25 mg/kg, weekly), and nab-paclitaxel (15 mg/kg, weekly; red arrows), or the triple combination of gemcitabine and nab-paclitaxel (as dosed for the monotherapies) plus K-80003 (20 mg/kg, twice weekly; blue arrows) for 3 weeks. Tumors were harvest at 3 weeks after treatment. Survival curves for mice that received different treatments (5 mice per group).
-
Biomater Adv
Development of a HER1/CP2c dual-targeting biopharmaceutical for HER1-overexpressing head and neck cancer. [Abstract]2026 Feb 18:183:214782. PMID: 41722284 -
Precis Clin Med
Agrimol B inhibits pancreatic ductal adenocarcinoma by induction of lethal mitophagy through decreasing mitochondrial transcription termination factor 3. [Abstract]2026 Mar 14;9(2):pbag009. PMID: 41978696 -
Int Immunopharmacol
Synergistic induction of ferroptosis by paclitaxel and sunitinib is mediated through SLC7A11 in lung cancer. [Abstract]2026 Jun 15:179:116595. PMID: 41955701 -
-
Mol Oncol
Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]2026 Jun 5. PMID: 42246237 -
-
Protocole
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Pureté et documentation
-
Fiche technique (265 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013 Sep 28;170(3):365-72. [Content Brief]
[2]. Yamamoto, Y., et al., (2011). Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. OncoTargets and therapy, 4, 123–136. [Content Brief]
[3]. Zhang, L., Marrano, P., et al., (2013). Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 19(21), 5972–5983. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Nab-Paclitaxel Related Classifications
HY-P99974 Related Classifications
Powered by Bioz